Roniciclib Inhibitor

Name: Roniciclib Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5755477
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5755477

Roniciclib is an inhibitor of pan-cyclin dependent kinase (IC50s: 5-25nM for CDK1, CDK2, CDK3, CDK4, CDK7, and CDK9). More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Roniciclib, Inhibitor

Full Product Name

Roniciclib

Product Synonym Names

BAY 1000394

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

430.44

Solubility

DMSO: 250mg/mL (580.80mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C18H21F3N4O3S

SMILES

C[C@@H](O)[C@H](OC1=NC(NC2=CC=C([S@@](=N)(C3CC3)=O)C=C2)=NC=C1C(F)(F)F)C

CAS Number

1223498-69-8

Target & IC50

Cdk1/cyclin B: ic50 7nM
CDK2/cyclinE: ic50 9nM
CDK4/cyclin D: ic50 11nM
CDK9/cyclinT1: ic50 5nM
CDK7/Cyclin H/MAT1: ic50 25nM

In Vitro

Roniciclib has low blood clearance rates in mouse, rat, and dog (0.51, 0.78, and 0.50 Lh-1kg-1, respectively). Roniciclib strongly inhibits the growth of HeLa-MaTu tumors that have been grown to a size of approximately 50mm2 before the start of treatment, Roniciclib (1.5 and 1mg/kg) treatment,slow tumor growth to T/C values of 0.15 and 0.62, respectively. The addition of Roniciclib to cisplatin causes a strong tumor growth inhibition with T/C values of 0.01 (1.0mg/kg Roniciclib) and -0.02 (1.5mg/kg Roniciclib) [1][2].

Product Categories/Family for Roniciclib, inhibitor

Cell Cycle/Checkpoint; CDK

Product References and Citations for Roniciclib, inhibitor

Siemeister G, et al. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment,upon oral application. Mol Cancer Ther. 2012 Oct;11(10):2265-73.
Siemeister G, et al. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment,upon oral application. Mol Cancer Ther. 2012 Oct;11(10):2265-73.
Lucking U, et al. The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment,of cancer. ChemMedChem. 2013 Jul;8(7):1067-85.
Lucking U, et al. The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment,of cancer. ChemMedChem. 2013 Jul;8(7):1067-85.

Other Notes

Small volumes of Roniciclib, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Roniciclib purchase

MBS5755477 is an inhibitor targeting Roniciclib.